Propagation of the yeast prion [PSIP rions (infectious proteins) are proteins that are normally soluble but autocatalytically propagate as amyloid, which is a fibrous polymer-like aggregate rich in -sheet secondary structure (1). Normally folded mammalian prion protein has a high ␣-helical content, but its aggregated form contains much more -sheet and is highly resistant to proteolysis. When this autocatalytic conversion occurs on a large scale in the central nervous system, the amyloid form accumulates and is associated with the neurodegeneration in fatal diseases such as scrapie in sheep, bovine spongiform encephalopathy in cows, and Creutzfeld-Jacob disease in humans (2). Other proteins form amyloid in an autocatalytic manner, but only prion protein is infectious.Prions also occur in yeast (3). The best-characterized yeast prion proteins are Sup35p, a translation termination factor, and Ure2p, which is involved in nitrogen metabolism (4). More recently, Rnq1p was identified as a prion protein, and New1p was shown to contain a domain that can substitute for the priondetermining region of Sup35p (5-7). Amyloidogenic yeast prion proteins have an Asn͞Gln-rich prion-forming domain that, like mammalian prion protein, can be converted to a -sheet-rich, protease-resistant conformation in an autocatalytic manner. When yeast cells containing soluble Sup35p, for example, are mated to cells containing the prion form of Sup35p, the soluble form is converted to the aggregated form, which then continues to propagate as the yeast divide. is not yet understood. Lindquist and colleagues (11, 13) have suggested that the ability of Hsp104 both to nucleate Sup35p aggregation and to break up these aggregates plays a role in maintaining [PSI ϩ ]. On the other hand, others have suggested that Hsp104 is required only to break up aggregates to replicate them so that they are passed on to daughter cells when yeast divide (14-16). It was further proposed that Hsp104 breaks up only the small aggregates, whereas large aggregates form dead-end complexes unable to propagate the prion trait (15,(17)(18)(19).Investigations into the mechanism of action of Hsp104 have been facilitated by experiments showing that Hsp104 in vivo can be inactivated by treating yeast with low levels of guanidinehydrochloride (Gdn) (20)(21)(22). Whereas it was demonstrated many years ago that such treatment cures [PSI ϩ ], recently it was shown that Gdn acts by inhibiting Hsp104 ATPase activity (23,24). Because Gdn inactivates Hsp104 immediately, kinetics of [PSI ϩ ] curing after this inactivation can be monitored straightforwardly. When growing cells are exposed to Gdn there is a lag phase during which no curing occurs followed by a linear increase in the number of cured cells over time (25).These kinetic studies have supported the model that Hsp104 acts by breaking up prion polymers, thereby generating new prion ''seeds.'' During the lag phase that occurs after Hsp104 activity is inhibited, the prion polymers or seeds are thought to grow in size but, failing to...